Recent advancements, notably the emergence of HER2-targeted ADC, have demonstrated improved survival outcomes in breast cancer patients with HER2 IHC scores of 1+ or 2+ (HER2-low when combined with knowledge of negative ERBB2 amplification status). Here, ERBB2 is linked to breast carcinoma.